Matt Gethers/20.380 HIV Project/Technical Paper/Yi Design

Download in Word: 

20.380 Final Paper Outline

I.	HIV epidemiology A.	HIV prevalence in the world B.	Prevalence in the US C.	Prevalence in developing countries

II. Clinical Course of disease A.	Presence of HIV: blood, seminal fluid, pre-ejaculate, vaginal secretions, cerebrospinal fluid, breast milk, saliva, tears B.	Transmission: sex, blood, IV, mother to child, breast feeding C.	Infection course i.	Acute phase ii. Asymptomatic phase iii. AIDS 1.	Lymphoid tissue destroyed 2.	Opportunistic infections 3.	Cancer

III. Cellular/molecular biology of disease – details of viral lifecycle A.	Host cells B.	Host cell receptors: CD4, Cxcr4 (T cell), Ccr5 (MO) C.	Viral life cycle i.	Entry, make dsDNA, integrate, transcription, processing, translation, packaging, budding D.	Structure i.	Vpr – docking and import ii. PR (protease)Pol iii. RT (reverse transcriptase) iv. NFkB – respond to T cell activation v.	TAR, Tat vi. IN (integrase), RNase H vii. Rev – mRNA export viii. capsid proteins IV. Current treatments A.	Diagnosis i.	ELISA ii. Western Blot iii. RT PCR B.	Drugs that inhibit… i.	Entry: Fuzeon ii. Reverse transcription 1.	Nucleoside thymadine analogues: chain terminator 2.	Non-nucleoside – bind active site iii. Integration: in clinical trials 1.	Gilead Science’s GS-9137 2.	Merck’s MK-0518 iv. Transcription: still in development 1.	Tat v.	Protein production & processing 1.	Protease C.	HAART – highly active anti-retroviral therapy D.	Bone marrow transfusion E.	siRNA F.	Issues with current drugs, no cure

V.	Red blood cell background A.	Structure B.	Differentiation from hematopoietic stem cell i.	In vivo ii. Past in vitro C.	Destruction in liver D.	Peripheral stem cells

VI. Brief past papers about why current treatments are insufficient (brief IP, details later).